146 related articles for article (PubMed ID: 18790789)
1. Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901.
Leyton J; Smith G; Lees M; Perumal M; Nguyen QD; Aigbirhio FI; Golovko O; He Q; Workman P; Aboagye EO
Mol Cancer Ther; 2008 Sep; 7(9):3112-21. PubMed ID: 18790789
[TBL] [Abstract][Full Text] [Related]
2. 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition.
Solit DB; Santos E; Pratilas CA; Lobo J; Moroz M; Cai S; Blasberg R; Sebolt-Leopold J; Larson S; Rosen N
Cancer Res; 2007 Dec; 67(23):11463-9. PubMed ID: 18056475
[TBL] [Abstract][Full Text] [Related]
3. In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
Leyton J; Alao JP; Da Costa M; Stavropoulou AV; Latigo JR; Perumal M; Pillai R; He Q; Atadja P; Lam EW; Workman P; Vigushin DM; Aboagye EO
Cancer Res; 2006 Aug; 66(15):7621-9. PubMed ID: 16885362
[TBL] [Abstract][Full Text] [Related]
4. [18F]FLT PET for non-invasive assessment of tumor sensitivity to chemotherapy: studies with experimental chemotherapy TP202377 in human cancer xenografts in mice.
Munk Jensen M; Erichsen KD; Björkling F; Madsen J; Jensen PB; Sehested M; Højgaard L; Kjær A
PLoS One; 2012; 7(11):e50618. PubMed ID: 23226334
[TBL] [Abstract][Full Text] [Related]
5. Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.
Moroz MA; Kochetkov T; Cai S; Wu J; Shamis M; Nair J; de Stanchina E; Serganova I; Schwartz GK; Banerjee D; Bertino JR; Blasberg RG
Clin Cancer Res; 2011 Mar; 17(5):1099-110. PubMed ID: 21245090
[TBL] [Abstract][Full Text] [Related]
6. The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.
Haagensen EJ; Thomas HD; Wilson I; Harnor SJ; Payne SL; Rennison T; Smith KM; Maxwell RJ; Newell DR
PLoS One; 2013; 8(12):e81763. PubMed ID: 24339963
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment.
Lee HJ; Oh SJ; Lee EJ; Chung JH; Kim Y; Ryu JS; Kim SY; Lee SJ; Moon DH; Kim TW
Cancer Chemother Pharmacol; 2015 May; 75(5):1005-13. PubMed ID: 25776904
[TBL] [Abstract][Full Text] [Related]
8. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo.
Henderson YC; Chen Y; Frederick MJ; Lai SY; Clayman GL
Mol Cancer Ther; 2010 Jul; 9(7):1968-76. PubMed ID: 20587665
[TBL] [Abstract][Full Text] [Related]
9. 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.
McKinley ET; Smith RA; Zhao P; Fu A; Saleh SA; Uddin MI; Washington MK; Coffey RJ; Manning HC
J Nucl Med; 2013 Mar; 54(3):424-30. PubMed ID: 23341544
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of 3'-deoxy-3'-[18F]-fluorothymidine (18F-FLT) kinetics correlated with thymidine kinase-1 expression and cell proliferation in newly diagnosed gliomas.
Shinomiya A; Kawai N; Okada M; Miyake K; Nakamura T; Kushida Y; Haba R; Kudomi N; Yamamoto Y; Tokuda M; Tamiya T
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):175-85. PubMed ID: 23229746
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation status of thymidine kinase 1 following antiproliferative drug treatment mediates 3'-deoxy-3'-[18F]-fluorothymidine cellular retention.
Sala R; Nguyen QD; Patel CB; Mann D; Steinke JH; Vilar R; Aboagye EO
PLoS One; 2014; 9(7):e101366. PubMed ID: 25003822
[TBL] [Abstract][Full Text] [Related]
12. 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography Depicts Heterogeneous Proliferation Pathology in Idiopathic Pulmonary Arterial Hypertension Patient Lung.
Ashek A; Spruijt OA; Harms HJ; Lammertsma AA; Cupitt J; Dubois O; Wharton J; Dabral S; Pullamsetti SS; Huisman MC; Frings V; Boellaard R; de Man FS; Botros L; Jansen S; Vonk Noordegraaf A; Wilkins MR; Bogaard HJ; Zhao L
Circ Cardiovasc Imaging; 2018 Aug; 11(8):e007402. PubMed ID: 30354494
[TBL] [Abstract][Full Text] [Related]
13. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
[TBL] [Abstract][Full Text] [Related]
14. [18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.
Jensen MM; Erichsen KD; Johnbeck CB; Björkling F; Madsen J; Jensen PB; Sehested M; Højgaard L; Kjær A
BMC Cancer; 2013 Apr; 13():168. PubMed ID: 23548101
[TBL] [Abstract][Full Text] [Related]
15. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
[TBL] [Abstract][Full Text] [Related]
16. Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography imaging.
Leyton J; Lockley M; Aerts JL; Baird SK; Aboagye EO; Lemoine NR; McNeish IA
Cancer Res; 2006 Sep; 66(18):9178-85. PubMed ID: 16982761
[TBL] [Abstract][Full Text] [Related]
17. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
[TBL] [Abstract][Full Text] [Related]
18. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.
Ciuffreda L; Del Bufalo D; Desideri M; Di Sanza C; Stoppacciaro A; Ricciardi MR; Chiaretti S; Tavolaro S; Benassi B; Bellacosa A; Foà R; Tafuri A; Cognetti F; Anichini A; Zupi G; Milella M
Neoplasia; 2009 Aug; 11(8):720-31. PubMed ID: 19649202
[TBL] [Abstract][Full Text] [Related]
19. Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo.
Leyton J; Latigo JR; Perumal M; Dhaliwal H; He Q; Aboagye EO
Cancer Res; 2005 May; 65(10):4202-10. PubMed ID: 15899811
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose- and 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography as biomarkers of therapy response in platinum-resistant ovarian cancer.
Perumal M; Stronach EA; Gabra H; Aboagye EO
Mol Imaging Biol; 2012 Dec; 14(6):753-61. PubMed ID: 22484552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
